比美吉珠单抗改善中轴型脊柱关节炎患者的躯体功能、睡眠、工作生产力和整体健康相关生活质量:两项3期研究结果
在BE MOBILE 1和2两项3期研究中,非放射学及放射学中轴型脊柱关节炎患者随机接受皮下比美吉珠单抗160 mg或安慰剂每4周一次,第16周时比美吉珠单抗组在BASFI、SF-36 PCS和ASQoL上较安慰剂显著改善(p<0.001),MOS-Sleep-R Index II和WPAI:axSpA数值上改善更大,应答持续至第52周。
要点
- 第16周比美吉珠单抗组BASFI、SF-36 PCS和ASQoL较安慰剂显著改善(p<0.001)。
- 第16周MOS-Sleep-R Index II和WPAI:axSpA评分为数值上更大改善。
- 第52周60%-70%比美吉珠单抗治疗患者达到BASFI≤4及SF-36 PCS、ASQoL有意义改善。
核心结论
- 比美吉珠单抗治疗使全中轴型脊柱关节炎疾病谱患者在第16周躯体功能、睡眠、工作生产力和整体健康相关生活质量早期改善,并持续至第52周。
研究设计与样本
- BE MOBILE 1和2两项3期研究,患者随机接受皮下比美吉珠单抗160 mg或安慰剂每4周一次,从第16周起所有患者接受比美吉珠单抗160 mg每4周一次。
主要发现
- 第16周,比美吉珠单抗随机组较安慰剂随机组在BASFI、SF-36 PCS和ASQoL上自基线的改善显著更大(p<0.001)。
- 第16周,比美吉珠单抗随机组较安慰剂随机组在MOS-Sleep-R Index II和WPAI:axSpA评分上数值上改善更大。
- 第16周,比美吉珠单抗随机组较安慰剂随机组更高比例患者达到BASFI(0至≤4)日益严格改善阈值及SF-36 PCS(自基线增加≥5分)和ASQoL(自基线下降≥4分)有意义改善阈值。
- 应答持续或进一步改善至第52周,60%-70%比美吉珠单抗治疗患者达到BASFI≤4及SF-36 PCS和ASQoL有意义改善,无论最初随机分配至比美吉珠单抗或安慰剂。
关键数值与推荐
- BASFI改善阈值:0至≤4。
- SF-36 PCS有意义改善阈值:自基线增加≥5分。
- ASQoL有意义改善阈值:自基线下降≥4分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the impact of bimekizumab on physical functioning, sleep, work productivity and overall health-related quality of life (HRQoL) in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA) in the phase 3 studies BE MOBILE 1 and 2. METHODS: Patients were randomised to subcutaneous bimekizumab 160 mg or placebo every 4 weeks; from Week 16, all patients received bimekizumab 160 mg every 4 weeks. We report the following outcomes to Week 52: Bath Ankylosing Spondylitis Functional Index (BASFI), Medical Outcomes Study Sleep Scale Revised (MOS-Sleep-R) Index II, Work Productivity and Activity Impairment: axSpA (WPAI:axSpA), Short Form-36 Physical and Mental Component Summary (SF-36 PCS/MCS) and Ankylosing Spondylitis Quality of Life (ASQoL). RESULTS: At Week 16, bimekizumab-randomised patients demonstrated significantly greater improvement from baseline versus placebo in BASFI, SF-36 PCS and ASQoL (p<0.001), and numerically greater improvements in MOS-Sleep-R Index II and WPAI:axSpA scores. Higher proportions of bimekizumab-randomised versus placebo-randomised patients at Week 16 achieved increasingly stringent thresholds for improvements in BASFI (0 to ≤4), and thresholds for meaningful improvements in SF-36 PCS (≥5-point increase from baseline) and ASQoL (≥4-point decrease from baseline). Responses were sustained or further improved to Week 52, where 60%-70% of bimekizumab-treated patients achieved BASFI ≤4 and meaningful improvements in SF-36 PCS and ASQoL, regardless of whether originally randomised to bimekizumab or placebo. CONCLUSION: Bimekizumab treatment led to early improvements in physical function, sleep, work productivity and overall HRQoL at Week 16 in patients across the full axSpA disease spectrum. Improvements were sustained to Week 52. TRIAL REGISTRATION NUMBERS: NCT03928704; NCT03928743.
引用
- Dubreuil M, Navarro-Compán V, Boonen A, et al. Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD Open. 2024. PMID: 38834351. doi:10.1136/rmdopen-2024-004202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。